CD276 and neoplasm: In previous studies, targeting CD276 and Neuropilin-1(NRP1) has achieved remarkable success in tumor immunotherapy (49, 50); combined with our finding that PDIA3 is significant correlated with the expression of CD276 as well as NRP1 in many cancer types, we speculate that the potential association between PDIA3 and CD276 is promising for our further investigation.